Riikka Katainen

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignee: Zora Biosciences Oy. Active years: 2015-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Riikka Katainen. Retrieved from https://idiyas.com/inventor/riikka-katainen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 15 (Patent Applications = 3)

% Patents Active = 86.7

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 13)

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 6(Granted Patents)

Location History:

Espoo, FI (2017)
Helsinki, FI (2015 - 2024)

Company Filing History:

15 out of 26

Zora Biosciences Oy

patents

Years Active: 2015-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12270816 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2025-04-08),

2. 12025623 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2024-07-02),

3. 10955427 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2021-03-23),

4. 10551394 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2020-02-04),

5. 10261101 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2019-04-16),

6. 9863965 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2018-01-09),

7. 9857386 - Lipidomic biomarkers for atherosclerosis and cardiovascular disease (2018-01-02),

8. 9841431 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2017-12-12),

9. 9664698 - Biomarkers for sensitive detection of statin-induced muscle toxicity (2017-05-30),

10. 9541565 - Biomarkers for sensitive detection of statin-induced muscle toxicity (2017-01-10),

11. 9459265 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment (2016-10-04),

12. 9423406 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2016-08-23),

13. 9201080 - Lipidomic biomarkers for identification of high-risk coronary artery disease patients (2015-12-01),

14. 9052328 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment (2015-06-09),

15. 9052327 - Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment (2015-06-09),

Title: The Innovative Mind of Riikka Katainen: Pioneering Biomarkers for Cardiovascular Diseases

Introduction

Riikka Katainen, based in Helsinki, Finland, is a prominent inventor with a remarkable portfolio of 15 patents. Her innovative contributions are particularly significant in the fields of lipidomics and cardiovascular disease research. Riikka's work is dedicated to enhancing the prediction, diagnosis, and treatment of severe cardiovascular diseases (CVD) through advanced biomarker identification.

Latest Patents

Among her latest patents, Riikka has developed methods for utilizing lipidomic biomarkers to identify high-risk coronary artery disease patients. One notable invention focuses on predicting severe CVD complications such as acute myocardial infarction (AMI) and CVD-related mortality by analyzing lipid concentrations in biological samples. This invention identifies specific lipid markers that demonstrate greater specificity and sensitivity compared to existing clinical markers. It also includes antibodies that target these lipids, providing a powerful tool for predicting, diagnosing, preventing, and treating CVD complications.

Additionally, Riikka has designed a patent centered on lipidomic biomarkers for diagnosing and predicting atherosclerosis and cardiovascular disease. This innovation also involves the detection of lipid concentrations or ratios, leading to the identification of lipid markers that surpass current clinical markers in terms of sensitivity and specificity. The invention includes kits that combine lipids and antibodies to assist in predicting and diagnosing these diseases.

Career Highlights

Riikka is a key figure at Zora Biosciences Oy, a company dedicated to advancing biomarker research and its applications in healthcare. Her patents mark significant advancements in understanding lipidomics and addressing cardiovascular health issues. Throughout her career, she has consistently applied her expertise to develop groundbreaking methodologies in biomedical research.

Collaborations

Working alongside esteemed colleagues such as Reijo Laaksonen and Kim Ekroos, Riikka has fostered a collaborative environment that enhances innovation at Zora Biosciences Oy. Together, they contribute to the growing body of research that seeks to transform how cardiovascular diseases are understood and treated.

Conclusion

Riikka Katainen's contributions to the field of cardiovascular disease research are both innovative and impactful. Through her numerous patents and collaborative efforts, she continues to pave the way for advanced diagnostic and therapeutic strategies, ultimately aiming to improve patient outcomes in cardiovascular health. Her work exemplifies the vital intersection of innovation and medical research, underscoring her role as a leading inventor in her field.

Profile summary based on public USPTO records.